

Pressemitteilung

The move to Nasdaq: Successful Public Offering of Evotec SE

Frankfurt a. M., 10.02.2022

Public offering at Nasdaq: Evotec SE

Evotec is an industry-leading and internationally active drug discovery and development partner for the pharmaceutical and biotechnology industries. Evotec's shares were previously traded in the Prime Standard of the Frankfurt Stock Exchange and included in the MDAX and TecDAX indices.

The U.S. public offering (dual listing) took place by way of a capital increase from authorized capital in the amount of 10,000,000 new shares, which were admitted to trading on Nasdaq in the form of 20,000,000 so-called American Depositary Shares (ADS). The underwriters also partially exercised the option granted to them to place up to 3,000,000 additional ADS (greenshoe).

The U.S. public offering reportedly raised total proceeds of approximately €500 million for Evotec, which will be used, among other things, to expand its biologics manufacturing capacity. In particular, the Nasdaq listing will enable Evotec to further increase its visibility in the world's biggest pharmaceutical market.

This deal marks another successful US public offering for the Finlex-Team, which has previously advised other top tier clients from the biotech and pharma industry.

The team advising Evotec includes Nathalie Wache (Financial Lines Expert), Florian Eckstein (Practice Lead IPOs and Capital Markets) and Sebastian Klapper (Founder & Managing Director) along with its US co-broker team of Woodruff Sawyer from San Francisco.

The following images are released for reprinting subject to editorial, non-commercial use.

Nathalie Wache | (Press photo)

Photo credits: Finlex GmbH

Florian Eckstein | (Press photo)

Photo credits: Finlex GmbH

Sebastian Klapper | (Press photo)

Photo credits: Finlex GmbH

About Finlex GmbH

Finlex - the online insurance platform for commercial and industrial clients - aims to be the leading digital marketplace for financial lines business segments throughout Europe. This includes D&O, cyber, legal expenses, fidelity, pecuniary loss liability and capital market transaction insurance. Finlex focuses on digitization, along with outstanding technical expertise.

The InsurTech Radar 2021, recently published by Oliver Wyman, considers Finlex one of the few 'scale-ups' with enormous potential. Scale-ups are start-ups that show rapid growth already after the initial phase.

Finlex is headquartered in Frankfurt am Main, with offices in Berlin, Barcelona, Düsseldorf and Vienna..

About Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

Finlex Press release 02/2022

Press contact:

Finlex GmbH

Denise Jetzki

Marketing Expert

E-Mail: marketing@finlex.de

Phone: +49 69 8700 142-0

finlex.de

Evotec SE

Hinnerk Rohwedder

Senior Specialist Corporate Communications

E-Mail: hinnerk.rohwedder@evotec.com

Phone: +49 40 560 81-281

evotec.com

